Incidence, economic burden, and treatment of acute respiratory tract infection in hematopoietic stem cell transplantation recipients using real world data in Japan: a retrospective claims data analysis

References

• Iida M, Kodera Y, Dodds A, Registry Committee of the Asia-Pacific Blood and Marrow Transplantation Group (APBMT), et al. Advances in hematopoietic stem cell transplantation in the Asia-Pacific region: the second report from APBMT 2005-2015. Bone Marrow Transplant. 2019;54(12):1973–1986.
   PubMed Web of Science ®Google Scholar
• Peña E, Souza CA, Escuissato DL, et al. Noninfectious pulmonary complications after hematopoietic stem cell transplantation: practical approach to imaging diagnosis. Radiographics. 2014;34(3):663–683.
   PubMed Web of Science ®Google Scholar
• Chi AK, Soubani AO, White AC, et al. An update on pulmonary complications of hematopoietic stem cell transplantation. Chest. 2013;144(6):1913–1922.
   PubMed Web of Science ®Google Scholar
• Sahin U, Toprak SK, Atilla PA, et al. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation. J Infect Chemother. 2016;22(8):505–514.
   PubMed Web of Science ®Google Scholar
• Boonyaratanakornkit J, Vivek M, Xie H, et al. Predictive value of respiratory viral detection in the upper respiratory tract for infection of the lower respiratory tract with hematopoietic stem cell transplantation. J Infect Dis. 2020;221(3):379–388.
   PubMed Web of Science ®Google Scholar
• Martino R, Porras RP, Rabella N, et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant. 2005;11(10):781–796.
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Rathod DB, Couch R. Respiratory viruses. In: Safdar A, editor. Principles and practice of cancer infectious diseases. Current Clinical Oncology. Totowa, NJ: Humana Press; 2011.
   Google Scholar
• Rajapreyar P, Kopp W, Randolph A. Acute respiratory failure and management. In: Duncan C, Talano JA, McArthur J, editors. Critical care of the pediatric immunocompromised hematology/oncology patient. Cham: Springer; 2019.
   Google Scholar
• Atilla E, Sahin D, Atilla PA, et al. Upper respiratory viral infections in patients with haematological malignancies after allogeneic haematopoietic stem cell transplantation: a retrospective study. Antivir Ther. 2018;23(6):523–527.
   PubMed Web of Science ®Google Scholar
• Pochon C, Voigt S. Respiratory virus infections in hematopoietic cell transplant recipients. Front Microbiol. 2018;9(3294):3294.
   PubMedGoogle Scholar
• Chen-Yoshikawa TF, Sugimoto S, Shiraishi T, et al. Prognostic factors in lung transplantation after hematopoietic stem cell transplantation. Transplantation. 2018;102(1):154–161.
   PubMed Web of Science ®Google Scholar
• Jones JA, Qazilbash MH, Shih YC, et al. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the nationwide inpatient sample. Cancer. 2008;112(5):1096–1105.
   PubMed Web of Science ®Google Scholar
• Saito AM, Cutler C, Zahrieh D, et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008;14(2):197–207.
   PubMed Web of Science ®Google Scholar
• Chakravarty SD, Abell J, Leone-Perkins M, et al. A novel qualitative study assessing Patient-Reported outcome measures among people living with psoriatic arthritis or ankylosing spondylitis. Rheumatol Ther. 2021;8(1):609–620.
   PubMed Web of Science ®Google Scholar
• OECD.Stat. Organisation For Economic Co-Operation and Development; 2022 [cited 2022 May 25]. Available from: https://stats.oecd.org/.
   Google Scholar
• Mikulska M, Del Bono V, Gandolfo N, et al. Epidemiology of viral respiratory tract infections in an outpatient haematology facility. Ann Hematol. 2014; 93(4):669–676.
   PubMed Web of Science ®Google Scholar
• Sim SA, Leung VKY, Ritchie D, et al. Viral respiratory tract infections in allogeneic hematopoietic stem cell transplantation recipients in the era of molecular testing. Biol Blood Marrow Transplant. 2018;24(7):1490–1496.
   PubMed Web of Science ®Google Scholar
• Cho S-Y, Lee H-J, Lee D-G. Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea. Korean J Intern Med. 2018;33(2):256–276.
   PubMed Web of Science ®Google Scholar
• Seto A, Atsuta Y, Kawashima N, et al. Impact of hospital length of stay on the risk of readmission and overall survival after allogeneic stem cell transplantation. Int J Hematol. 2018;108(3):290–297.
   PubMed Web of Science ®Google Scholar
• Maher OM, Silva JG, Huh WW, et al. Etiologies and impact of readmission rates in the first 180 days after hematopoietic stem cell transplantation in children, adolescents, and young adults. Pediatr Hematol Oncol. 2017;39(8):609–613.
   Google Scholar
• Marinelli T, Wee LYA, Rowe E, et al. Respiratory viruses cause late morbidity in recipients of hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020;26(4):782–788.
   PubMed Web of Science ®Google Scholar
• Godara A, Siddiqui NS, Munigala S, et al. Length of stay and hospital costs for patients undergoing allogeneic stem-cell transplantation. JCO Oncol Pract. 2021;17(3):e355–e368.
   PubMedGoogle Scholar
• Sundaramurthi T, Sundaramurthi T. Predictors of length of hospital stay and readmission in hematologic stem cell transplant recipients [Doctoral dissertation]. Baltimore: University of Maryland; 2015 [cited 2021 Jul 23]. Available from https://archive.hshsl.umaryland.edu/handle/10713/4606.;en_US.
   Google Scholar
• Yong MK, Tio SY, Valentine J, et al. The economic and health utilization cost of clinically significant cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation. Blood. 2019;134(Supplement_1):3437–3437.
   Google Scholar
• Ghantoji SS, Karanth S, El Haddad L, et al. Clinical and economic burden of respiratory viral infections in hematopoietic stem cell transplant recipients: the MD Anderson experience. Open Forum Infect Dis. 2017;4(suppl_1):S319–S319.
   Google Scholar
• Ueno R, Nishimura S, Fujimoto G, et al. The clinical and economic burden of cytomegalovirus management post allogeneic hematopoietic stem cell transplantation in Japan – a retrospective database study. Curr Med Res Opin. 2019;35(12):2089–2096.
   PubMed Web of Science ®Google Scholar
• Schain F, Batyrbekova N, Liwing J, et al. Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease. Eur J Health Econ. 2021;22(1):169–180.
   PubMed Web of Science ®Google Scholar
• Yu J, Lal L, Anderson A, et al. Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Support Care Cancer. 2020;28(11):5491–5499.
   PubMed Web of Science ®Google Scholar
• Taylor AL, Wright JT. Jr. Should ethnicity serve as the basis for clinical trial design? Importance of race/ethnicity in clinical trials: lessons from the African-American heart failure trial (A-HeFT), the African-American study of kidney disease and hypertension (AASK), and the antihypertensive and Lipid-Lowering treatment to prevent heart attack trial (ALLHAT). Circulation. 2005;112(23):3654–3660.
   PubMed Web of Science ®Google Scholar